Advertisement
Advertisement
U.S. markets open in 4 hours 46 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Fennec Pharmaceuticals Inc. (FENC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.83-0.20 (-2.49%)
At close: 04:00PM EDT
7.83 0.00 (0.00%)
After hours: 05:31PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close8.03
Open7.81
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range7.58 - 8.00
52 Week Range3.82 - 10.08
Volume249,244
Avg. Volume111,230
Market Cap203.891M
Beta (5Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)-0.63
Earnings DateNov 08, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for FENC

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Fennec Pharmaceuticals Inc.
    Analyst Report: AMGEN Inc.Amgen, based in Thousand Oaks, California, is a leading global biotech company. Its key products include Repatha, Kyprolis, Prolia, Xgeva, Neulasta, and Enbrel. The shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • American City Business Journals

    RTP pharma to see $20M infusion on heels of drug winning approval

    After falling short on two previous attempts, a drugmaker in Research Triangle Park has secured regulatory approval for its lead product and is now set to see major dollars to support commercialization.

  • Benzinga

    After Two FDA Rejections, Fennec Pharma Lead Drug Scores US Approval For Chemo-Induced Hearing Loss

    The FDA approved Fennec Pharmaceuticals Inc's (NASDAQ: FENC) Pedmark to reduce the risk of chemo-induced ototoxicity in pediatric patients. Pedmark is indicated for pediatric patients one month of age, and older who have localized, non-metastatic solid tumors and have been treated with cisplatin infusions. This approval makes Pedmark the first and only treatment approved by the FDA in this area of significant unmet medical need. The approval comes after receiving two FDA complete response letter

  • GlobeNewswire

    Fennec Pharmaceuticals Announces FDA Approval of PEDMARK® (Sodium Thiosulfate Injection)

    ~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ RESEARCH TRIANGLE PARK, N.C., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved PEDMARK® (sodium thiosulfate injection) to reduce the risk of ototoxicity a

Advertisement
Advertisement